| JAM-A as a prognostic factor and new therapeutic target in multiple myeloma AG Solimando, A Brandl, K Mattenheimer, C Graf, M Ritz, A Ruckdeschel, ... Leukemia 32 (3), 736-743, 2018 | 72 | 2018 |
| Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects K Meinhardt, I Kroeger, R Bauer, F Ganss, I Ovsiy, J Rothamer, M Büttner, ... Oncoimmunology 4 (1), e981483, 2015 | 50 | 2015 |
| Cereblon enhancer methylation and IMiD resistance in multiple myeloma L Haertle, S Barrio, U Munawar, S Han, X Zhou, C Vogt, RA Fernández, ... Blood, The Journal of the American Society of Hematology 138 (18), 1721-1726, 2021 | 36 | 2021 |
| Subgroup-independent mapping of renal cell carcinoma—machine learning reveals prognostic mitochondrial gene signature beyond histopathologic boundaries A Marquardt, AG Solimando, A Kerscher, M Bittrich, C Kalogirou, H Kübler, ... Frontiers in oncology 11, 621278, 2021 | 35 | 2021 |
| A multicenter retrospective study of 223 patients with t (14; 16) in multiple myeloma S Goldman‐Mazur, A Jurczyszyn, JJ Castillo, A Waszczuk‐Gajda, ... American journal of hematology 95 (5), 503-509, 2020 | 28 | 2020 |
| Impact of borderline resectability in pancreatic head cancer on patient survival: biology matters according to the new international consensus criteria F Anger, A Döring, J van Dam, JF Lock, I Klein, M Bittrich, CT Germer, ... Annals of surgical oncology 28, 2325-2336, 2021 | 24 | 2021 |
| Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy S Danhof, S Strifler, D Hose, M Kortüm, M Bittrich, J Hefner, H Einsele, ... Journal of Cancer Research and Clinical Oncology 145, 561-571, 2019 | 20 | 2019 |
| Multiple myeloma in patients up to 30 years of age: a multicenter retrospective study of 52 cases A Jurczyszyn, J Davila, KM Kortüm, DS Jayabalan, R Vij, M Fiala, ... Leukemia & Lymphoma 60 (2), 471-476, 2019 | 20 | 2019 |
| Monoclonal gammopathy of renal significance (MGRS): Real‐world data on outcomes and prognostic factors A Gozzetti, A Guarnieri, E Zamagni, E Zakharova, D Coriu, M Bittrich, ... American Journal of Hematology 97 (7), 877-884, 2022 | 17 | 2022 |
| Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two … D Hose, M Schreder, J Hefner, M Bittrich, S Danhof, S Strifler, MT Krauth, ... Journal of Cancer Research and Clinical Oncology 147, 205-212, 2021 | 15 | 2021 |
| Protocol for M3P: A Comprehensive and Clinical Oriented Targeted Sequencing Panel for Routine Molecular Analysis in Multiple Myeloma S Barrio, M DáVia, L Bruins, T Stühmer, T Steinbrunn, M Bittrich, ... Multiple Myeloma: Methods and Protocols, 117-128, 2018 | 11 | 2018 |
| Minimal residual disease and imaging‐guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma D Böckle, P Tabares, X Zhou, S Schimanski, MJ Steinhardt, M Bittrich, ... British Journal of Haematology 198 (3), 515-522, 2022 | 10 | 2022 |
| Kinetics of renal function during induction in newly diagnosed multiple myeloma: results of two prospective studies by the German Myeloma Study Group DSMM F Bachmann, M Schreder, M Engelhardt, C Langer, D Wolleschak, ... Cancers 13 (6), 1322, 2021 | 10 | 2021 |
| Exploration of artificial intelligence use with ARIES in multiple myeloma research S Loda, J Krebs, S Danhof, M Schreder, AG Solimando, S Strifler, ... Journal of Clinical Medicine 8 (7), 999, 2019 | 10 | 2019 |
| Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam A Straub, A Vollmer, TT Lâm, RC Brands, M Stapf, O Scherf-Clavel, ... Clinical Oral Investigations 26 (12), 7033-7044, 2022 | 9 | 2022 |
| Aplastic anemia as a roadmap for bone marrow failure: an overview and a clinical workflow AG Solimando, C Palumbo, MV Pragnell, M Bittrich, A Argentiero, M Krebs International Journal of Molecular Sciences 23 (19), 11765, 2022 | 7 | 2022 |
| HGF-Induced PD-L1 expression in head and neck cancer: Preclinical and clinical findings V Boschert, J Teusch, A Aljasem, P Schmucker, N Klenk, A Straub, ... International Journal of Molecular Sciences 21 (22), 8770, 2020 | 7 | 2020 |
| Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients S Goldman-Mazur, A Jurczyszyn, JJ Castillo, A Waszczuk-Gajda, ... Leukemia & Lymphoma 61 (8), 1885-1893, 2020 | 7 | 2020 |
| Carfilzomib, lenalidomide, and dexamethasone (KRd) versus elotuzumab and KRd in transplant-eligible patients with newly diagnosed multiple myeloma: Post-induction response and … S Knop, T Stuebig, M Kull, R Greil, N Steiner, F Bassermann, A Nogai, ... Journal of Clinical Oncology 41 (16_suppl), 8000-8000, 2023 | 6 | 2023 |
| Mechanisms of proteasome inhibitor resistance selected by clonal evolution in multiple myeloma L Haertle, S Barrio, M Simicek, U Munawar, R Sanchez, M Bittrich, ... Blood 134, 4349, 2019 | 5 | 2019 |
Antonio Giovanni SolimandoBari University, Department of Precision and Regenerative Medicine and Ionian AreaVerified email at uniba.it
